Good综合征合并免疫介导性内耳病及系统性硬皮病1例并文献复习
Good Syndrome Complicated with Immune-Mediated Inner Ear Disease and Systemic Sclerosis: A Case Report and Literature Review
DOI: 10.12677/acm.2025.15113157, PDF,    科研立项经费支持
作者: 薛婉莹, 张 青, 陶千山*:安徽医科大学第二附属医院血液内科,安徽 合肥
关键词: Good综合征免疫介导性内耳病系统性硬皮病胸腺瘤Good Syndrome Immune-Mediated Inner Ear Disease Systemic Sclerosis Thymoma
摘要: 回顾性分析该院血液内科收治的1例Good综合征(GS)合并免疫介导性内耳病(IMIED)及系统性硬皮病(SSc)患者的临床资料及治疗措施。患者,男,32岁,因右侧听力下降就诊,既往有胸腺瘤手术史,经检查确诊为Good综合征,结合听力检查及病因排除,考虑合并IMIED,病程中患者出现系统性硬皮病。患者接受药物保守治疗、糖皮质激素冲击及免疫球蛋白补充等综合治疗后,患者感染及免疫缺陷病情较前好转,听力损害未完全恢复,后患者因感染于院外死亡。对于存在免疫缺陷基础的患者,若出现突发性听力下降或皮肤纤维化等症状,需考虑合并IMIED或SSc的可能,为临床提供了一定的借鉴意义。
Abstract: This study retrospectively analyzed the clinical data and treatment of a patient with Good syndrome (GS) complicated with immune-mediated inner ear disease (IMIED) and systemic sclerosis (SSc) admitted to the Department of Hematology of our hospital. A 32-year-old male presented with right-sided hearing loss and had a history of thymoma surgery. The patient was diagnosed with GS after comprehensive examinations. Combined with audiological tests and exclusion of other etiologies, IMIED was considered as a complication. During the disease course, systemic sclerosis developed. The patient received comprehensive treatments including conservative drug therapy, glucocorticoid pulse therapy, and immunoglobulin supplementation, which resulted in improved infection and immunodeficiency conditions; however, hearing impairment was not fully recovered. The patient eventually died of infection outside the hospital. For patients with underlying immunodeficiency, the possibility of concurrent IMIED or SSc should be considered when sudden hearing loss or skin fibrosis occurs. This case provides valuable clinical insights.
文章引用:薛婉莹, 张青, 陶千山. Good综合征合并免疫介导性内耳病及系统性硬皮病1例并文献复习[J]. 临床医学进展, 2025, 15(11): 757-762. https://doi.org/10.12677/acm.2025.15113157

参考文献

[1] Kabir, A., Alizadehfar, R. and Tsoukas, C.M. (2022) Good’s Syndrome: Time to Move on from Reviewing the Past. Frontiers in Immunology, 12, Article ID: 815710. [Google Scholar] [CrossRef] [PubMed]
[2] Dong, J., Gao, W., Teng, G., Tian, Y. and Wang, H. (2017) Characteristics of Good’s Syndrome in China: A Systematic Review. Chinese Medical Journal, 130, 1604-1609. [Google Scholar] [CrossRef] [PubMed]
[3] Kelesidis, T. and Yang, O. (2010) Good’s Syndrome Remains a Mystery after 55 Years: A Systematic Review of the Scientific Evidence. Clinical Immunology, 135, 347-363. [Google Scholar] [CrossRef] [PubMed]
[4] Hanafusa, T., Umegaki, N., Yamaguchi, Y. and Katayama, I. (2010) Good’s Syndrome (Hypogammaglobulinemia with Thymoma) Presenting Intractable Opportunistic Infections and Hyperkeratotic Lichen Planus. The Journal of Dermatology, 37, 171-174. [Google Scholar] [CrossRef] [PubMed]
[5] Liu, K. and Cowlishaw, J.L. (2013) Beware of the Patient with Thymectomy: Good’s Syndrome in a Patient Presenting with Diarrhea. ACG Case Reports Journal, 1, 33-35. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, M., Zhang, P., Li, Q. and Kong, C. (2025) Investigating the Process of Autoimmune Inner Ear Disease: Unveiling the Intricacies of Pathogenesis and Therapeutic Strategies. International Journal of Medical Sciences, 22, 179-187. [Google Scholar] [CrossRef] [PubMed]
[7] Miwa, T. and Okano, T. (2022) Role of Inner Ear Macrophages and Autoimmune/Autoinflammatory Mechanisms in the Pathophysiology of Inner Ear Disease. Frontiers in Neurology, 13, Article ID: 861992. [Google Scholar] [CrossRef] [PubMed]
[8] Jimenez, S.A., Mendoza, F.A. and Piera-Velazquez, S. (2025) A Review of Recent Studies on the Pathogenesis of Systemic Sclerosis: Focus on Fibrosis Pathways. Frontiers in Immunology, 16, Article ID: 1551911. [Google Scholar] [CrossRef] [PubMed]
[9] Engesser, J., Wang, H., Kapffer, S., Kaffke, A., Peters, A., Paust, H., et al. (2024) S1PR1 Mediates Th17 Cell Migration from the Thymus to the Skin in Health and Disease. Frontiers in Immunology, 15, Article ID: 1473130. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, S., Gang, X., Yang, S., Cui, M., Sun, L., Li, Z., et al. (2021) The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases. Frontiers in Immunology, 12, Article ID: 678355. [Google Scholar] [CrossRef] [PubMed]
[11] Stinson, W.A., Miner, C.A., Zhao, F.R., Lundgren, A.J., Poddar, S. and Miner, J.J. (2022) The IFN-γ Receptor Promotes Immune Dysregulation and Disease in STING Gain-of-Function Mice. JCI Insight, 7, e155250. [Google Scholar] [CrossRef] [PubMed]
[12] Lin, M., Ji, X., Lv, Y., Cui, D. and Xie, J. (2023) The Roles of TRAF3 in Immune Responses. Disease Markers, 2023, Article ID: 7787803. [Google Scholar] [CrossRef] [PubMed]
[13] Fochi, S., Bergamo, E., Serena, M., Mutascio, S., Journo, C., Mahieux, R., et al. (2019) TRAF3 Is Required for NF-κB Pathway Activation Mediated by HTLV Tax Proteins. Frontiers in Microbiology, 10, Article No. 1302. [Google Scholar] [CrossRef] [PubMed]
[14] Strober, W. and Watanabe, T. (2011) NOD2, an Intracellular Innate Immune Sensor Involved in Host Defense and Crohn’s Disease. Mucosal Immunology, 4, 484-495. [Google Scholar] [CrossRef] [PubMed]
[15] Huangfu, L., Li, R., Huang, Y. and Wang, S. (2023) The IL-17 Family in Diseases: From Bench to Bedside. Signal Transduction and Targeted Therapy, 8, Article No. 402. [Google Scholar] [CrossRef] [PubMed]
[16] Mebarki, M., Abadie, C., Larghero, J. and Cras, A. (2021) Human Umbilical Cord-Derived Mesenchymal Stem/Stromal Cells: A Promising Candidate for the Development of Advanced Therapy Medicinal Products. Stem Cell Research & Therapy, 12, Article No. 152. [Google Scholar] [CrossRef] [PubMed]
[17] Yao, X.Y., Xie, L., Cai, Y., et al. (2022) Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial. Frontiers in Neurology, 13, Article ID: 860083.
[18] Han, X., Liao, R., Li, X., Zhang, C., Huo, S., Qin, L., et al. (2025) Mesenchymal Stem Cells in Treating Human Diseases: Molecular Mechanisms and Clinical Studies. Signal Transduction and Targeted Therapy, 10, Article No. 262. [Google Scholar] [CrossRef] [PubMed]
[19] Zaripova, L.N., Midgley, A., Christmas, S.E., Beresford, M.W., Pain, C., Baildam, E.M., et al. (2023) Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases. International Journal of Molecular Sciences, 24, Article No. 16040. [Google Scholar] [CrossRef] [PubMed]
[20] Chen, B., Chen, Z., He, M., Zhang, L., Yang, L. and Wei, L. (2024) Recent Advances in the Role of Mesenchymal Stem Cells as Modulators in Autoinflammatory Diseases. Frontiers in Immunology, 15, Article ID: 1525380. [Google Scholar] [CrossRef] [PubMed]
[21] Gao, Y., Ji, Z., Zhao, J. and Gu, J. (2025) Therapeutic Potential of Mesenchymal Stem Cells for Fungal Infections: Mechanisms, Applications, and Challenges. Frontiers in Microbiology, 16, Article ID: 1554917. [Google Scholar] [CrossRef] [PubMed]
[22] Baranovskii, D.S., Klabukov, I.D., Arguchinskaya, N.V., Yakimova, A.O., Kisel, A.A., Yatsenko, E.M., et al. (2022) Adverse Events, Side Effects and Complications in Mesenchymal Stromal Cell-Based Therapies. Stem Cell Investigation, 9, 7. [Google Scholar] [CrossRef] [PubMed]